Sunitinib-induced hand-foot syndrome in a Kashmiri male

Authors

  • Mohammad H Mir Department of Medical Oncology, Sheri Kashmir Institute of Medical Sciences, Srinagar, J & K, India
  • Parvaiz A Rather Department of Dermatology, STD & Leprosy, Govt. Medical College, Srinagar, J & K, India
  • Farhana Bagdadi Department of Internal Medicine, Sheri Kashmir Institute of Medical Sciences, Srinagar, J & K, India

DOI:

https://doi.org/10.66344/jpad.v24i2.246

Keywords:

Sunitinib, tyrosine kinase inhibitor, renal cell carcinoma, hand-foot syndrome

Abstract

Sunitinib belongs to multiple tyrosine kinase inhibitor class of novel targeted therapies used for metastatic solid tumours including renal cell carcinoma. A variety of systemic, as well as, cutaneous side effects due to sunitinib have been described including the hand foot syndrome. We report sunitinib-induced hand foot syndrome in a 65-year-old Kashmiri male and review the literature.

References

1. Degen A, Alter M, Schenck F et al. The hand-foot-syndrome associated with medical tumor therapy - classification and management. J Dtsch Dermatol Ges. 2010;8:652-61.

2. Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology. 2009;77:257-71.

3. Jeong JS, Yun JH, Yoon SJ et al. Two cases of hand-foot syndrome induced by sunitinib. Korean J Dermatol. 2008;46:1236-39.

4. Zuehlke RL. Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica. 1974;148:90-2.

5. Hueso L, Sanmartin O, Nagore E et al. Chemotherapy induced acral erythema: A clinical and histopathological study of 44 cases. Actas Dermosifiliogr. 2008;99:281-90.

6. Demircay Z, Gurbuz O, Alpdogan T et al. Chemotherapy-induced acral erythema in leukemic patients: a report of 15 cases. Int J Dermatol. 1997;36:593-8.

7. Apisarnthanarax N, Duvic MM. Dermatologic complications of cancer chemotherapy. In: Kufe DW, Pollock RE, Weichselbaum RR et al., editors. Holland-Frei Cancer Medicine. 6th edition. Hamilton (ON): BC Decker; 2003.

8. Webster-Gandy JD, How C, Harrold K. Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre. Eur J Oncol Nurs. 2007;11:238-46.

9. Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol. 2008;19:1955-61.

10. Baack BR, Burgdorf WH. Chemotherapy-induced acral erythema. J Am Acad Dermatol. 1991;24:457-61.

Downloads

Published

02.12.2016

Issue

Vol. 24 No. 2 (2014): April - June

Section

Case Reports

License

Copyright (c) 2016 Mohammad H Mir, Parvaiz A Rather, Farhana Bagdadi

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.

How to Cite

1.
Sunitinib-induced hand-foot syndrome in a Kashmiri male. J Pak Assoc Dermatol [Internet]. 2016 Dec. 2 [cited 2026 Jul. 28];24(2):180-2. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/246